Dr Charles Brenner on the longevity understanding disconnect, the best interventions for longevity, and the NR trials he’d like to see.
The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world’s leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.
One of those thought leaders is Charles Brenner, the biochemist whose work on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, includes the discovery of nicotinamide riboside (NR) kinase pathway and the resulting tech that led to the development of NR as an NAD-booster.
As Eric Verdin did recently, Brenner is one for driving the longevity debate, even if it causes more than a few ripples, and in cautioning against overstating progress, he is a significant calibration point for our industry (Twitter wars, notwithstanding). We were able to grab a few moments with Brenner at LIC to find out more about his thoughts on the current state of play.
Visit Longevity. Technology — https://bit.ly/3PwtH8Y
Follow Longevity. Technology on:
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf
Comments are closed.